279 related articles for article (PubMed ID: 26684030)
1. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
[TBL] [Abstract][Full Text] [Related]
2. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
[TBL] [Abstract][Full Text] [Related]
5. Platelet-activating factor podoplanin: from discovery to drug development.
Takemoto A; Miyata K; Fujita N
Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
[TBL] [Abstract][Full Text] [Related]
7. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
Ogasawara S; Kaneko MK; Price JE; Kato Y
Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment.
Miyata K; Takagi S; Sato S; Morioka H; Shiba K; Minamisawa T; Takami M; Fujita N
Cancer Med; 2014 Dec; 3(6):1595-604. PubMed ID: 25132683
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
10. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (
Ukaji T; Takemoto A; Katayama R; Takeuchi K; Fujita N
Oncotarget; 2018 Sep; 9(70):33322-33336. PubMed ID: 30279963
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
[TBL] [Abstract][Full Text] [Related]
12. A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis.
Takemoto A; Okitaka M; Takagi S; Takami M; Sato S; Nishio M; Okumura S; Fujita N
Sci Rep; 2017 Feb; 7():42186. PubMed ID: 28176852
[TBL] [Abstract][Full Text] [Related]
13. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.
Takagi S; Sato S; Oh-hara T; Takami M; Koike S; Mishima Y; Hatake K; Fujita N
PLoS One; 2013; 8(8):e73609. PubMed ID: 23991201
[TBL] [Abstract][Full Text] [Related]
14. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis.
Kunita A; Kashima TG; Morishita Y; Fukayama M; Kato Y; Tsuruo T; Fujita N
Am J Pathol; 2007 Apr; 170(4):1337-47. PubMed ID: 17392172
[TBL] [Abstract][Full Text] [Related]
15. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis.
Takagi S; Oh-hara T; Sato S; Gong B; Takami M; Fujita N
Int J Cancer; 2014 Jun; 134(11):2605-14. PubMed ID: 24222607
[TBL] [Abstract][Full Text] [Related]
16. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
[TBL] [Abstract][Full Text] [Related]
18. Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.
Oki H; Ogasawara S; Kaneko MK; Takagi M; Yamauchi M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Feb; 34(1):44-50. PubMed ID: 25723283
[TBL] [Abstract][Full Text] [Related]
19. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
Sheng M; Sun R; Fu J; Lu G
BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690
[TBL] [Abstract][Full Text] [Related]
20. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
Xu M; Wang X; Pan Y; Zhao X; Yan B; Ruan C; Xia L; Zhao Y
BMC Cancer; 2019 Jun; 19(1):599. PubMed ID: 31208371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
